Palbociclib, a clinically‐approved CDK4/6 inhibitor, is used to induce senescence in a murine TNBC model, resulting in both tumor growth arrest and increased heat sensitivity due to HSP70 downregulation. The gene discussed is CDK4; the disease is neoplasm.